Article

VisiJet expects quick approval for corneal tissue tool

VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.

VisiJet Inc. has filed a 510K statement with the FDA for approval of the Epi-Tome, a next-generation ophthalmic surgical tool designed for cutting and separating corneal tissue.

The company has secured worldwide distribution rights from Gebauer Medizintechnik GmbH of Neuhausen, Germany. The product has earned the CE mark and is being sold in Europe and Korea.

VisiJet expects an expedited FDA approval by fall.OT

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Telemedicine and genetics for resource-efficient care with Louis R. Pasquale, MD
© 2025 MJH Life Sciences

All rights reserved.